Sugi Predict

Sugi Predict / Compounds / SCHEMBL642178

SCHEMBL642178

SCHEMBL642178

O=c1[nH]cnc2ccc(O)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 8/20 1.00
▸ CHEK1 O14757 1/20 0.64
▸ PIM1 P11309 1/20 0.64
▸ AKT1 P31749 1/20 0.64
▸ FLT3 P36888 1/20 0.64
▸ PIM3 Q86V86 1/20 0.64
▸ SLC2A1 P11166 1/20 0.61
▸ IP6K1 Q92551 9/20 0.58
▸ PDPK1 O15530 1/20 0.56
▸ CA12 O43570 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ CA9 Q16790 1/20 0.56
▸ TNKS2 Q9H2K2 1/20 0.56
▸ IP6K3 Q96PC2 5/20 0.54
▸ IP6K2 Q9UHH9 3/20 0.54
▸ ACVR1 Q04771 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29873118 0.85 PARP1 (0.74) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL1663179 0.85 PARP1 (0.74) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL8622180 0.81 ACVR1 (0.73) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL29701199 0.78 PARP1 (1.00) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL2081677 0.78 PARP1 (1.00) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL29709603 0.78 PARP1 (1.00) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL216176 0.78 PARP1 (1.00) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL2191067 0.78 PARP1 (1.00) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL30110907 0.78 PARP1 (0.64) PARP1CHEK1PIM1AKT1FLT3
SCHEMBL29605527 0.78 PARP1 (1.00) PARP1CHEK1PIM1AKT1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4263518-B1 NEW QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-04-01 — — EP disclosed
US-12570615-B2 Quinazolinone derivatives HOFFMANN-LA ROCHE INC. 2026-03-10 — — US disclosed
US-12486253-B2 Therapeutics for the degradation of mutant BRAF C4 THERAPEUTICS, INC. (US) 2025-12-02 — — US disclosed
US-20250136595-A1 ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2025-05-01 — — US disclosed
US-20250115580-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2025-04-10 — — US disclosed
EP-4476211-A1 ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2024-12-18 — — EP disclosed
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) DANA-FARBER CANCER INSTITUTE, INC. 2024-11-14 — — US disclosed
CN-118401507-A Inhibitors targeting ubiquitin-specific protease 7 (USP 7) 丹娜法伯癌症研究院 2024-07-26 — — CN disclosed
CN-111247152-B Cyclic iminopyrimidine derivatives as kinase inhibitors 璧辰医药技术股份有限公司 2024-07-16 — — CN disclosed
US-20240199581-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2024-06-20 — — US disclosed
US-5821246-A USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER ZENECA LIMITED (GB) 1998-10-13 — — US disclosed
CN-1183774-A Trisubstd phenyl derivs CIBA GEIGY AG (CH) 1998-06-03 — — CN disclosed
EP-0815087-A1 TRISUBSTITUTED PHENYL DERIVATIVES Novartis AG (CH) 1998-01-07 — — EP disclosed
EP-0790986-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1997-08-27 — — EP disclosed
WO-1996028430-A1 TRISUBSTITUTED PHENYL DERIVATIVES NOVARTIS AG (CH) 1996-09-19 — — WO disclosed
WO-1996015118-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1996-05-23 — — WO disclosed
US-5457105-A anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) ZENECA LIMITED (GB) 1995-10-10 — — US disclosed
EP-0023594-B1 TRANS-QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND MEDICAMENTS CONTAINING THESE DERIVATIVES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-05-16 — — EP disclosed
US-4281127-A USEFUL AS ANTIALLERGENS HOFFMANN-LA ROCHE INC. (US) 1981-07-28 — — US disclosed
EP-0023594-A1 Trans-Quinazoline derivatives, processes for their preparation, intermediates and medicaments containing these derivatives F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-02-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136595-A1 ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ERBB2, ERBB3, ERBB4 PARP1 2023/4885CHEK1 37/4885PIM1 1769/4885
US-20240199581-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF BRAF, NRAS, KRAS PARP1 3715/4885CHEK1 410/4885PIM1 2078/4885
US-12486253-B2 Therapeutics for the degradation of mutant BRAF BRAF, NRAS, KRAS PARP1 3715/4885CHEK1 410/4885PIM1 2078/4885
US-20240376076-A1 INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) USP7, USP47, USP2 PARP1 1909/4885CHEK1 1582/4885PIM1 2537/4885
US-20250115580-A1 THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF BRAF, NRAS, KRAS PARP1 3715/4885CHEK1 410/4885PIM1 2078/4885
US-12570615-B2 Quinazolinone derivatives ABL1, NQO2, CNR1 PARP1 720/4885CHEK1 1159/4885PIM1 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.